INTENDED USE & DESCRIPTION

For use as quantitative controls for the determination of cytokine concentrations in biological fluids. Concentrations have been assigned using R&D Systems’ Quantikine? kits. Controls are prepared in diluted porcine serum with preservatives. They contain recombinant human cytokines at low, medium and high concentrations. Controls are supplied lyophilized.

STORAGE & STABILITY

Unreconstituted Controls should be stored at 2-8 °C and are stable for at least 6 months from date of receipt. Depending on the analyte of interest, reconstituted controls may be stable when stored at < -20 °C. Users should evaluate the frozen stability of the controls in their application or discard after use.

REAGENT PREPARATION

Reconstitute each vial with the volume of deionized or distilled water indicated on the product datasheet.

PROCEDURE & EXPECTED VALUES

Controls should be assayed in the same manner as unknown specimens.

The acceptable ranges for the analytes in these controls are printed on the product datasheet. Due to possible variations in techniques and methodologies, it is recommended that each laboratory determine its own target range. Laboratories using other test systems should establish their own acceptable ranges as these assays may produce different values.

TECHNICAL HINTS & LIMITATIONS OF THE PROCEDURE 

? The ranges were determined using R&D Systems’ Quantikine kits. If expected values are not obtained, verify that the lot numbers on the vials correspond with the lot numbers listed above and the correct volume of deionized or distilled water was used for reconstitution of the controls. 

? The results obtained with these controls depend upon several factors associated with methods and instrumentation. Test systems other than those supplied by R&D Systems may result in values that differ from those printed on this product datasheet.

Preparation and Storage

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Butyrylcholinesterase/BCHE

Butyrylcholinesterase (BCHE) is a major acetylcholine hydrolyzing enzyme in the circulation. Although it is present in significant amounts (~3 mg/L) in human plasma, no endogenous physiological substrate has been described for this enzyme. It can degrade a large number of ester-containing compounds in addition to acylcholines. Thus, it is likely to play significant pharmacological and toxicological roles. It is thought to be involved in the pathological process of Alzheimer's disease (AD) by depleting acetylcholine. In contrast to ACHE, it attenuates amyloid fibril formation   in vitro. BCHE inhibitors have been used to delay symptoms of AD patients by virtue of their ability to enhance acetylcholine availability. Its involvement in a cholinergic anti-inflammatory pathway connect BCHE and ACHE with a possible marker of low-grade systemic inflammation observed in Type-2 diabetes, obesity, hypertension, coronary heart disease, and AD. BCHE can exist in monomeric and multimeric forms. The expressed recombinant mouse BCHE contains multiple forms that consist of soluble monomers, dimers, and tetramers.

• Entrez Gene IDs:

  590 (Human); 12038 (Mouse)

• Alternate Names:

  Acylcholine acylhydrolase; BCHE; Butyrylcholine esterase; Butyrylcholinesterase; CHE1; CHE1cholinesterase; Choline esterase II; cholinesterase 1; E1; EC 3.1.1.8; Pseudocholinesterase